CELL AND GENE THERAPY

Biocytogen Enters into Antibody Agreement with ADC Therapeutics

Biocytogen | November 28, 2022 | Read time : 03:00 min

Biocytogen Enters
Biocytogen Pharmaceuticals Co., Ltd. announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a later date for global ADC development and commercialization. Biocytogen reserves all global rights for these antibodies beyond ADC development. Biocytogen will receive an upfront payment. For each option exercised, Biocytogen will be entitled to an option-exercise fee, and development and commercial milestone payments, which potentially total tens of millions of US dollars, as well as single-digit royalties on net sales.

Under the agreement, Biocytogen will provide ADC Therapeutics with monoclonal and/or biparatopic antibodies directed against three tumor targets, generated through Biocytogen’s Project Integrum. ADC Therapeutics will carry out feasibility studies and be responsible for further development and commercialization of the ADC products if the company exercises an option.

ADC Therapeutics is a leader in the development and commercialization of ADCs. We believe this collaboration with ADC Therapeutics will underscore the value of Biocytogen’s proprietary antibody discovery and screening platforms. We’ve been dedicated to expanding the possibilities of antibody-based therapeutics in disease treatment, through the exploration of new types of targets and modalities through Project Integrum. The combination of Biocytogen’s strength in antibody development with ADC Therapeutics’ expertise and track record in payload and linker technology may lead to the generation of novel ADC medicines for unmet medical needs in the future.”

Dr. Yuelei Shen, President and CEO of Biocytogen

“We are pleased to enter this collaboration with Biocytogen as we continue expanding our toolbox to realize the full potential of our ADC platform,” said Patrick van Berkel, PhD, Chief Scientific Officer of ADC Therapeutics. “We look forward to evaluating the fully human antibodies from Biocytogen’s proprietary discovery platform, which have the potential to accelerate the development of our novel ADCs.”

About Biocytogen
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. 

About ADC Therapeutics
ADC Therapeutics is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates. The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.



Spotlight

Recruitment, retention, and diversity are critical elements of clinical trials that, if insufficient, can jeopardize successful trial completion. 

Spotlight

Recruitment, retention, and diversity are critical elements of clinical trials that, if insufficient, can jeopardize successful trial completion. 

Related News

INDUSTRIAL IMPACT, MEDICAL

SOPHiA and MSKCC Partner to Combine Cancer Analysis Technology for Liquid Biopsies

SOPHiA GENETICS | January 13, 2023

SOPHiA GENETICSTM, a leading cloud-native software firm in the healthcare industry, recently announced that it has partnered with Memorial Sloan Kettering Cancer Center (MSKCC) to provide physicians and researchers with new testing and analytic capabilities. The collaboration includes the incorporation of proprietary Comprehensive Genomic Panel (CGP) sequencing tests, such as MSK-ACCESS®, which SOPHiA GENETICS will market as the first comprehensive ctDNA liquid biopsy test powered by the SOPHiA DDMTM platform. By integrating predictive algorithms, the power of the global SOPHiA GENETICS network, and the clinical knowledge of MSK in cancer genomics, specialists hope to broaden their access to capabilities for precision cancer analysis. SOPHiA GENETICS and MSK will work together to further develop MSK-ACCESS®, ensuring that the solution leverages the advanced analytics of the SOPHiA DDMTM platform. The enhanced assay will be designed to align with the latest guidelines and clinical trial data reflecting major actionable biomarkers. As part of this agreement, SOPHiA GENETICS plans to develop a new clinical-genomic, cloud-native analytics platform that enhances the impact of MSK’s extensive precision oncology data. This involves the application of sophisticated machine learning algorithms to examine vast amounts of multimodal data points to get new insights. The new SOPHiA CarePathTM module's goal, in conjunction with MSK's CGP sequencing assays, aims to improve cancer care worldwide. About SOPHiA GENETICS SOPHiA GENETICS is a cloud-native software company committed to establishing data-driven medicine as the standard of care and for life sciences research. It offers the SOPHiA DDM™ as a cloud-based SaaS platform that enables healthcare organizations to obtain quick and accurate insights from their data. The platform is currently being used by a broad network of hospitals, laboratories, and biopharma institutions globally. By applying its technology to diseases such as cancer and hereditary disorders, it facilitates the integration of genomic and phenotypic data, which is crucial for supporting discoveries, treatment decisions, and drug development activities. In addition, SOPHiA GENETICS supports its mission of bringing data analytics solutions to market through the global adoption of SOPHiA AI, built using techniques such as statistical inference, pattern recognition, and machine learning.

Read More

MEDTECH, INDUSTRIAL IMPACT

Oxford Biomedica Solutions forms new partnerships with three biotechnology companies

Oxford Biomedica Solutions LLC | December 15, 2022

Oxford Biomedica Solutions LLC, an AAV manufacturing and innovation company, announced today that it has signed agreements with three additional U.S. based, biotechnology companies. This places Oxford Biomedica Solutions ahead of the previously stated target of two new partners by the end of the calendar year. Under these additional agreements, Oxford Biomedica Solutions will provide its full platform offering to support the new partners’ gene therapy programs, which cover a broad range of indications, including CNS, autoimmune, oncology, muscular, and rare metabolic disease. Oxford Biomedica Solutions’ proven platform has demonstrated consistent bioreactor titers of E15 vg/L and achieved over 90% fully intact vector for multiple constructs. Oxford Biomedica Solutions’ innovative platform potentially enables accelerated drug development of high quality products produced at significantly more doses per batch. The platform drives down the number of batches needed, as well as the cost, for both clinical and commercial operations, to deliver much needed therapies to patients sooner. In line with preparing and managing the increasing activities and demand, we have recently opened a new 24,000sqft expansion space that includes dedicated analytical development lab space to accommodate the growth in new projects and partners, as well as continued development innovation. Additionally, this new space will also house a commercial GMP Drug Substance footprint that will incorporate multiple 500L bioreactors and allow Oxford Biomedica Solutions to offer a single facility option for both clinical and commercial supply of high quality and high titer vector. “These new partnerships are a true validation of the Oxford Biomedica Solutions team, our capabilities, and AAV plug-and-play platform. We started this endeavor because we were confident that we can help develop successful gene therapy products with our platform, expertise, and the care that our team delivers on every product. We are excited this is now coming to fruition, and we are giving our new partners and their patients access to high quality product with the efficiency and productivity of our platform addressing the increase in demand that we are seeing.” Tim Kelly, Chair and CEO of Oxford Biomedica Solutions About Oxford Biomedica Solutions Oxford Biomedica Solutions offers a platform that can achieve both high titer and high product quality vector for partners. The platform has already been proven with six separate new product INDs and CTAs. High titer, high product quality, proven expertise, and speed are the foundation of the platform. This unique platform and fully integrated end-to-end capabilities, from vector design and process development through to clinical trials, are now available to partners.

Read More

AI

Benchling Reinforces Security Commitment with Type 2 SOC 2

Benchling | January 27, 2023

On January 27, 2023, Benchling, the R&D cloud that powers the biotechnology sector, announced that it has passed the System and Organization Controls (SOC) 2 certification. Schellman, an independent Certified Public Accounting (CPA) firm, conducted the Type 2 SOC 2 test according to the AICPA's SOC 2 standards. Type 2 SOC 2 evaluates the design and operational performance of an organization's security processes and controls to meet its security goals and customer commitments during a predetermined evaluation period. Constant monitoring, evaluation, and modification of the requirements and security measures guarantee a secure environment for doing business. The CISO at Benchling, Zach Powers, said, "Biotechs are managing an evolving landscape of security and compliance risks, and they require trusted software partners to help them meet these demands." He added, "At Benchling, we make the security, privacy, and compliance of our customers' sensitive data a company-wide, critical investment, not only through Type 2 SOC 2, but also through our best-in-class security team, our trust-but-verify processes, and our adherence to global compliance standards." (Source – PR Newswire) Benchling's R&D Cloud is the biotech R&D platform of choice, trusted by over 1,000 organizations worldwide in highly regulated areas such as biopharmaceuticals, agribusiness, industrials, and consumer packaged goods. Benchling is used by customers to securely store, standardize, and analyze crucial data related to the design and development of innovative biotech products. Benchling's objective is to protect client data; hence, the firm utilizes sophisticated data security and privacy protections and complies with tight regulatory regulations such as the NIST Cybersecurity Framework. The organization is also ISO 27001 certified. The successful completion of Benchling's Type 2 SOC 2 inspection assures that its biotech clients can conduct crucial R&D work in the Benchling R&D Cloud while following the highest security requirements. About Benchling Benchling is a San Francisco-based firm that focuses on private and public life science cooperation by developing cloud-based software tools for digital DNA sequence editing, planning and performing experiments, evaluating data, and sharing research. More than 200,000 scientists from over 1,000 firms and 7,500 university and research institutions worldwide have used the Benchling R&D Cloud to create breakthrough discoveries and deliver the next generation of medicines, foods, and materials to market more quickly. In addition, the R&D cloud assists these companies in modernizing their scientific processes and accelerating their cooperation to transform the complexity of biology into world-changing outcomes.

Read More